---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114196"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:41:50.562864+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q3 GAAP net income $50M; LINZESS Rx demand up 10% YoY, surpasses 1M quarterly scripts

## Summary
- GAAP net income of $50M ($0.28 diluted EPS); adjusted EBITDA $69M; total revenue $108.6M vs. $103.7M YoY.
- LINZESS prescription demand grew 10% YoY in Q3; exceeded 1M total prescriptions in a quarter for first time.
- Plan to submit sNDA to FDA for functional constipation in pediatric patients (ages 6-17) by end of 2022.
- Reaffirms FY2022 guidance: total revenue $420-$430M, adjusted EBITDA >$250M, LINZESS net sales low single digit % growth.
- Ended Q3 with $574M cash; no debt on balance sheet; strong liquidity position.

## SEC filing metadata
- accession: 0001104659-22-114196
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/0001104659-22-114196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/tm2229423d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114196
- JSON: https://secwatch.observer/filing/0001104659-22-114196.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114196.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2022 results: revenue $108,637, net income $50,317, EPS $0.33. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $108,637
  - Net income: $50,317
  - EPS: $0.33
  - Guidance: reaffirmed
  - Result: reported results
  source text: allocation continue to position our company for growth.” Third Quarter 2022 Financial Highlights 1 (in thousands, except for per share amounts) 3Q 2022 3Q 2021 Total revenues $ 108,637 $ 103,747 Total operating expenses 40,164 38,576 GAAP net income 50,317 55,845 GAAP net income per share – basic 0.33 0.34 GAAP net income per share – diluted 0.28 0.34 Adjusted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465922114196/0001104659-22-114196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.